Provenge in Combination with Radium-223
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.
Clinical Pearls:
- Both companies that developed the drugs have approved a trial design
- The trial will be small and have immunologic endpoints to help physicians better understand the mechanisms of action behind combining radiation therapy and immunotherapy
- Researchers hypothesize that radiation may be able to induce epitopes that can trigger better immune responses
- There is good preclinical data that suggests that radiation and immunotherapy may have interesting interplay
Recent Videos
Related Content
